DIACORDON - ELISA
Bridge from
Science to Business
Diagenics SE ist ein biopharmazeutisches Unternehmen mit Sitz in Luxemburg.
Unser einzigartiges Modell schlägt die Brücke zwischen Wirtschaft und Wissenschaft.

 

 

 

 

  • Facebook: diagenics
  • Twitter: Diagenics
  • External Link: plus.google.com/112288944010267009430
DIACORDON - ELISA
PDF Print E-mail

LABORATORY TEST

Diacordon - ElISA

DIACORDON™ is a blood test for the early detection of cardiac infarction. It works on an enzyme basis and can detect Glycogen-Phosphorylase Isoenzym BB (GPBB) via an antibody owned by Diagenics.

The enzyme GPBB enters the bloodstream as soon as a myocardial ischemia occurs. In the long run such an insufficient oxygen supply leads to a necrosis of the affected cells and/or eventually to an infarction. Moreover, the detection of GPBB in the blood provides information about the progress of the coronary syndromes (including unstable angina pectoris) and classic cases of heart attack. In this way it contributes decisively to the diagnosis of heart infarction patients.

There are already markers, such as myoglobin and troponin, which contribute to the diagnosis and are routinely applied in cases of a myocardial infarction. Myoglobin, however, has the disadvantage of not being heart specific. It can also be detected after damages of the skeletal muscles or after acute renal failure and thus does not give a clear answer. Troponin, on the other hand, is heart specific, but can only be detected three to six hours after the first symptoms (chest pain).

GPBB is not only heart specific but also early detectable, i.e. within the first hour. For the case of acute coronary syndromes this is a vital advantage, since a quick and exact diagnosis can save lives.